Pterostilbene Side Effects

Reported Pterostilbene side effects

Pterostilbene is among the best-tolerated polyphenol supplements available, with an extensive human safety database from clinical trials and post-marketing experience. Common and uncommon adverse effects include: Gastrointestinal effects (most common): Mild stomach upset, nausea, bloating, or loose stools occur in 5-10% of users, particularly at higher doses or when taken on an empty stomach. Taking pterostilbene with food generally resolves these symptoms. Severe gastrointestinal reactions are rare. Headache: Mild headaches are reported by a small percentage of users, typically transient and resolving with continued use or dose reduction. LDL cholesterol elevation (dose-dependent): The most specific documented concern with pterostilbene is a modest LDL cholesterol elevation observed at high doses (250 mg/day) in the Riche 2014 analysis. The mechanism is believed to relate to PPAR-alpha agonism affecting hepatic cholesterol metabolism. At doses of 50-150 mg/day (the range used in most commercial products) the LDL signal is not clinically apparent. Users with existing cardiovascular disease or familial hyperlipidemia should have lipid profiles monitored during pterostilbene supplementation and consider doses at the lower end of the range. Blood pressure reduction (desired or adverse): Pterostilbene reduces blood pressure in hypertensive individuals by approximately 5-10 mmHg systolic. In normotensive individuals or those already taking antihypertensive medications, the additional blood pressure reduction can produce symptoms of hypotension — dizziness, lightheadedness, particularly with postural changes, headache, or fatigue. Monitoring is recommended when starting pterostilbene in patients taking antihypertensive medications. Interactions with anticoagulants and antiplatelets: Pterostilbene has mild antiplatelet activity and may theoretically enhance bleeding tendency in patients taking warfarin, clopidogrel, aspirin, or direct oral anticoagulants. Clinical significance is likely modest at typical supplementation doses but warrants awareness particularly in patients on multiple agents affecting hemostasis. Discontinue pterostilbene at least 7 days before surgical procedures. Interactions with CYP enzyme-metabolized drugs: Pterostilbene can modestly inhibit some cytochrome P450 enzymes including CYP1A2 and CYP2C9 at high doses. Clinical relevance for most medications at supplementation doses is minimal but could theoretically affect drugs with narrow therapeutic indices. Allergic reactions: Allergic reactions to pterostilbene itself are extremely rare. Occasional reactions to formulation excipients (lecithin in phytosome products, coloring agents) have been reported. Pregnancy and lactation: Pterostilbene has not been studied for safety in pregnancy or lactation. Avoid use during these periods. Hormone-sensitive conditions: Pterostilbene has some estrogen receptor modulating activity in preclinical studies. Clinical significance in humans is uncertain. Women with estrogen-dependent cancer history should consult their oncology team before supplementation. Drug discontinuation syndromes: Abrupt discontinuation of pterostilbene is not associated with any withdrawal syndrome or rebound phenomenon. Users can start and stop without tapering. Long-term safety: Long-term (>1 year) safety data are less extensive than short-term trials, though the Basis product has been marketed since 2014 with no major safety signals emerging from post-marketing experience. Doses at 50-100 mg/day appear well-tolerated indefinitely. Pediatric use: Pediatric safety and efficacy have not been established. Do not use in children. Kidney and liver function: Pterostilbene does not appear to produce hepatotoxicity or nephrotoxicity at typical supplementation doses. Users with pre-existing hepatic or renal impairment should consult clinicians before supplementation. Surgery considerations: Due to potential antiplatelet effects, discontinue pterostilbene 7-10 days before surgical procedures to minimize bleeding risk. Overall tolerability grade: Pterostilbene's tolerability profile is excellent compared to many supplement categories, with the main clinically-relevant concerns being the LDL elevation at high doses, potential antihypertensive interactions, and mild antiplatelet effects. Most users taking 50-150 mg daily experience no adverse effects whatsoever.

When to continue, reduce, or stop Pterostilbene

Pterostilbene contraindications

Absolute contraindications: Pregnancy and lactation: No safety data exist for pterostilbene during pregnancy or breastfeeding. Avoid use. Known allergy to stilbenes or pterostilbene: Extremely rare but absolute contraindication. Severe familial hypercholesterolemia with baseline elevated LDL: The LDL elevation signal at high pterostilbene doses is undesirable in patients with already-elevated LDL; alternative supplementation should be preferred. Relative contraindications (discuss with physician before use): Active cardiovascular disease with hypertension on multiple antihypertensives: Additional blood pressure reduction may produce hypotension; physician-guided dose titration required. Uncontrolled hypertension with significant orthostatic symptoms: Pterostilbene's blood pressure-lowering effect may exacerbate orthostatic hypotension. Anticoagulation therapy (warfarin, direct oral anticoagulants): Mild antiplatelet effects may improve bleeding risk; discuss risk-benefit with physician. Perioperative period: Discontinue pterostilbene 7-10 days before surgical procedures to minimize bleeding risk. Hormone-dependent cancer history (estrogen-receptor-positive breast cancer): Theoretical concern about weak estrogen-modulating activity; discuss with oncology team. Severe hepatic impairment: Clinical data are limited; theoretical concern about altered metabolism. Cyclosporine or tacrolimus therapy: Potential CYP interaction; use only with physician supervision and drug level monitoring. Upcoming clinical trial participation: Polyphenol supplementation can confound some biomarker-based trials; disclose to researchers. Caution populations: Adults over 75 years: Favor intermediate over advanced protocols; monitor for orthostatic symptoms, falls, and polypharmacy interactions. Diabetes with insulin or sulfonylurea therapy: Monitor blood glucose more frequently; pterostilbene may improve hypoglycemia risk through AMPK activation. Chronic kidney disease stage 3+: No specific adjustment required for pterostilbene but warrants clinical oversight for overall supplementation regimen. Users with multiple polypharmacy agents: The theoretical CYP and transporter effects of pterostilbene have unknown but probably modest clinical relevance across diverse drug regimens; disclose all medications to prescribing physicians. Drug interactions requiring monitoring: Warfarin and other anticoagulants (mild antiplatelet effect) Antihypertensives (additive blood pressure reduction) Cyclosporine, tacrolimus (theoretical CYP modulation) Statins (monitor lipid panel given pterostilbene LDL signal at high doses) Insulin and sulfonylureas (monitor glucose for hypoglycemia) Other CYP1A2 or CYP2C9 substrates with narrow therapeutic indices Discontinue immediately and seek medical attention if: Severe allergic reaction (rash, difficulty breathing, facial swelling) Significant unexplained bleeding or bruising Severe hypotension (syncope, near-syncope) Jaundice or severe abdominal pain suggestive of hepatic dysfunction

Why vendor quality drives Pterostilbene side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Pterostilbene side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .